Health care resource use and costs for Crohn's disease before and after infliximab therapy

Canadian Journal of Gastroenterology

Volumn 25, Issue 9, 2011, Pages 497-502

  Loomes, Dustin E ^a   Teshima, Christopher ^a   Jacobs, Philip ^a   Fedorak, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Crohn's disease; Economic analysis; Health care cost; Health policy; Inflammatory bowel disease; Infliximab

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; DISEASE DURATION; DRUG COST; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FOLLOW UP; GASTROINTESTINAL SURGERY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; INFUSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PRIORITY JOURNAL; X RAY;

EID: 80054724965     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/157604     Document Type: Article

References (29)

1. Sadowski DC, Bernstein CN, Bitton A, et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405. (Pubitemid 29205403)
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
6. Koelewijn C, Schrijvers A, Oldenburg B. Infliximab use in patients with Crohn's disease: Quality of life, costs and resource use. Netherlands J Med 2006;64:212-8. (Pubitemid 44203650)
7. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: A population-based study. Am J Gastroenterol 2006;101:1559-68. (Pubitemid 43980630)
8. Blomqvist P, Ekbom A. Inflammatory bowel diseases: Health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134-9. (Pubitemid 27523846)
9. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: A payor perspective. Am J Gastroenterology 2000;95:1955-60.
10. Hay JW, Hay AR. Inflammatory bowel disease: Costs-of-illness. J Clin Gastroenterol 1992;14:309-17.
11. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000;95:677-83. (Pubitemid 30123901)
12. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000;95:524-30. (Pubitemid 30106188)
13. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: Impact on health care resources in the UK. Eur J Gastroenterol Heaptol 2005;17:1047-52. (Pubitemid 41423997)
14. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9. (Pubitemid 40523539)
15. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002;35:151-6. (Pubitemid 34815854)
16. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. (Pubitemid 38182297)
17. Saro C, De La Coba C, Casado M, Morales J, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Thera 2007;26:1313-23. (Pubitemid 350064013)
18. Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: A payor perspective. Value in health. J Int Soc Pharmacoecon and Outcomes Res 2008;11:820-9.
19. Cohen RD, Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2006;35:867-82. (Pubitemid 44791838)
20. Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348-52.
21. Health Authority Funding and Financial Accountability. Health Costing in Alberta. Annual Report. Edmonton: Alberta Health and Wellness, 2006.
22. Alberta Health Care Insurance Plan. Medical Procedure List. Schedule of Medical Benefits. Edmonton: Alberta Health and Wellness, 2006.
23. Statistics Canada. Consumer price indexes for Canada, monthly. 〈www.bankofcanada.ca/en/rates/inflation-calc.html〉 (Accessed on May 30, 2010).
24. XE Currency Conversion Chart. 〈www.xe.com/currencycharts/〉 (Accessed on May 30, 2010).
25. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: A single-centre UK experience. Aliment Pharmacol Ther 2010;32:1357-63.
26. Taxonera C, Rodrigo L, Casellas F, et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009;43:950-6.
27. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
28. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8. (Pubitemid 37305364)
29. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6. (Pubitemid 38679108)